MYCOSIS FUNGOIDES

This early-phase trial tests a genetically modified virus (VSV-hIFNβ-NIS) combined with an immunotherapy drug (cemiplimab) in adults with relapsed or refractory T-cell lymphoma. The virus is designed to kill cancer cells while leaving healthy cells alone, and the immunotherapy he…

This early-stage trial tests an experimental drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have worsened after standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug throug…

This trial tests whether combining the drug mogamulizumab with low-dose total skin electron beam therapy works better than either alone for people with mycosis fungoides or Sezary syndrome, two rare types of skin lymphoma. Participants receive both treatments over several weeks. …

This early-stage trial tests a new gene therapy for certain T-cell lymphomas that have come back or not responded to treatment. The therapy uses a patient's own white blood cells, modified to attack cancer cells that carry a protein called CCR4. Up to 60 adults will receive the m…

This study tests whether combining two drugs, pembrolizumab and mogamulizumab, can shrink or control advanced cutaneous T-cell lymphoma (a type of skin cancer) that has returned or not responded to prior therapy. About 23 adults with stage IIB to IVB disease will receive the drug…

This early-phase trial tests whether combining a topical immune-boosting cream (imiquimod) with local radiation can better treat mycosis fungoides, a rare skin lymphoma. About 25 adults with stable but active disease who have tried at least one other therapy will receive the crea…

This study tests whether a treatment called photopheresis can improve early-stage cutaneous T-cell lymphoma (a type of skin lymphoma). Normally used for advanced disease, researchers want to see if using it earlier helps clear skin lesions. About 74 adults with stage IA to IIA my…

This phase II trial tests whether ultra low dose radiation can control skin lesions in people with mycosis fungoides, a type of lymphoma. About 50 participants will receive very low doses of radiation to their skin lesions. The goal is to see if this gentler approach works as wel…

This Phase 3 trial tests a gel called HyBryte, which is activated by visible light, for treating cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. About 80 adults with early-stage CTCL will apply the gel or a placebo twice a week for 18 weeks, then receive light treat…

This study is testing whether a lower dose of the drug brentuximab vedotin can still effectively treat three types of skin lymphoma: mycosis fungoides, Sezary syndrome, and lymphomatoid papulosis. The goal is to see if reducing the dose can maintain benefits while possibly loweri…

This early-phase trial tests an investigational drug called ropeginterferon in 38 adults with cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Participants must have tried at least two prior treatments without success. The main goals are to find the safest dose and s…

This study tests a drug called pacritinib in 100 people with T-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. Participants take the drug and are monitored with scans and skin asse…

This study tests a combination of ultra-low-dose radiation to the whole skin and a drug called brentuximab vedotin for people with mycosis fungoides, a rare type of skin lymphoma. The treatment is given every three months for a year. The goal is to see if this approach can better…

This study tests a drug called golidocitnib in people with slow-growing but hard-to-treat T/NK-cell lymphomas that have not responded to standard therapy. The goal is to see if the drug can shrink or control the cancer. About 48 adults will take the drug by mouth, and researchers…

This early-phase trial tests an oral drug called TLN-254 in about 50 adults with relapsed or refractory T-cell lymphoma. The main goal is to see if the drug can shrink tumors and how safe it is. Participants take the drug by mouth on a set schedule, and researchers will monitor r…

This early-stage trial is testing a new form of fenretinide (a vitamin A-like drug) given by IV for people with T-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The study has two parts: first, finding the safest dose in small groups of patients, …

This study is tracking how safe and effective the drug mogamulizumab (Poteligeo) is for adults with two rare types of skin lymphoma: mycosis fungoides and Sézary syndrome. Researchers will monitor 15 participants in routine care settings for side effects and how well the drug con…

This study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…

This study follows 100 people diagnosed before age 20 with mycosis fungoides or lymphomatoid papulosis, rare skin conditions. Researchers will check their health and ask about long-term effects. The goal is to understand how these diseases progress over time, not to test a new tr…

This study collects blood, urine, and skin samples from 200 adults with cutaneous T-cell lymphoma, eczema, or atopic dermatitis. The samples are stored and used for current and future research, such as studying proteins in the blood and tissue. Participants must have one of these…

This study is collecting medical information from 2000 people with advanced mycosis fungoides or Sézary syndrome, two rare types of skin lymphoma. The goal is to create a tool that helps doctors predict which patients are at higher or lower risk, so they can tailor treatments mor…